Epidermal growth factor (EGF) comprises a structurally related family of proteins containing heparin-binding EGF-like growth factor (HB-EGF) and transforming growth factor alpha (TGF␣) that regulates the development of dopaminergic neurons as well as monoamine metabolism. We assessed the contribution of EGF to schizophrenia by measuring EGF family protein levels in postmortem brains and in fresh serum of schizophrenic patients and control subjects. EGF protein levels were decreased in the prefrontal cortex and striatum of schizophrenic patients, whereas the levels of HB-EGF and TGF␣ were not significantly different in any of the regions examined. Conversely, EGF receptor expression was elevated in the prefrontal cortex. Serum EGF levels were markedly reduced in schizophrenic patients, even in young, drug-free patients. Chronic treatment of animals with the antipsychotic drug haloperidol had no influence on EGF levels in the brain or serum. These findings suggest that there is abnormal EGF production in various central and peripheral tissues of patients with both acute and chronic schizophrenia. EGF might thus provide a molecular substrate for the pathologic manifestation of the illness, although additional studies are required to determine a potential link between impaired EGF signaling and the pathology/etiology of schizophrenia.
Introduction
Epidermal growth factor (EGF) and structurally related peptides such as heparin-binding EGF-like growth factor (HB-EGF) and transforming growth factor alpha (TGF␣) are mitogenic peptides for various types of cells 1 and regulatory factors for cellular migration and differentiation in peripheral organs. 2 In the brain, EGF family members serve as neurotrophic molecules to enhance stem cell proliferation and neuronal differentiation, and influence synaptic plasticity, including hippocampal long-term potentiation. [3] [4] [5] [6] In situ hybridization techniques reveal widespread expression of HB-EGF mRNA in neurons and oligodendrocytes, especially in the cerebellum, hippocampus, cerebral cortex, subventricular area, and brain stem nuclei. glial cells. 8 In contrast, there are relatively low levels of EGF mRNA expression in the brain. 9 EGF receptors (EGFR) are widely present in both the developing and mature central nervous system (CNS). [10] [11] [12] EGF and structurally related peptides have been studied extensively with respect to the growth and survival of midbrain dopaminergic neurons. 4, [13] [14] [15] [16] 18 Gene-targeting studies have confirmed the importance of EGF in the general development of brain structures as well as in monoaminergic function. [17] [18] [19] [20] Observations in transgenic mice overexpressing TGF␣ emphasize the biologic significance of the EGF family for the development and function of monoaminergic neurons. 19, 20 The above observations, together with the findings from gene manipulation studies, suggest that impaired signaling of the EGF family might be associated with various brain diseases. [19] [20] [21] Neurotrophic factors and cytokines are involved in psychiatric diseases, with current evidence suggesting that they mutually interact and strongly influence synaptic development and transmitter release. [22] [23] [24] [25] [26] [27] [28] [29] We recently reported that brain-derived neurotrophic factor (BDNF) enhances the chemical development of preand postsynaptic machinery. 30, 31 In turn, EGF and related family members suppress BDNF expression and perturb the chemical development of central synapses. [31] [32] [33] The biologic significance of the EGF family in various psychiatric diseases, however, remains to be determined in patients.
To assess the potential contribution of the EGF family to schizophrenia, we quantified EGF protein along with that of its related peptides in postmortem brains and in serum. Changes in EGF protein levels were correlated with brain EGFR (ErbB family) expression in schizophrenic patients.
Materials and methods
Human tissue and serum sampling Postmortem brain tissue was collected from 32 patients with chronic schizophrenia (23 men, nine women; age 62.4 ± 12.6 years, mean ± SD) and from 19 controls (11 men, eight women; 61.5 ± 11.7 years) who had no history of neuropsychiatric disorders (Table 1) . Almost all schizophrenics had taken antipsychotic drugs for prolonged periods. The postmortem diagnosis of schizophrenia, based on the reported psychiatric symptoms, corresponded to the DSM-VI categories (American Psychiatric Association). In each case, the left cerebral hemisphere was fixed in formalin for diagnostic examination and the right hemisphere was frozen at −80°C. All the pathologic analyses were performed at the authors' institutes. Tissue samples were taken from postmortem brains that did not exhibit neurodegenerative abnormalities with conventional pathologic staining. 34 The prefrontal cortex (approximately Brodmann area 46), putamen, hippocampus (including all the CA regions and dentate gyrus), and posterior cingulate cortex were identified in frozen coronal slices according to a published human brain atlas. 35 Serum was collected from 55 physically healthy schizophrenic patients and controls. In the analysis of serum EGF, serum from four drug-naive and two drugwashout (over 14 months) patients was also included as an independent group. The mean age and gender ratio was similar in the patient and control groups (see Table 2 ). Healthy controls were recruited randomly from volunteer hospital staff, nurses, and residents. Blood samples were collected between 0800 to 1130 h into glass tubes without anticoagulant. The blood was allowed to clot at room temperature, and the serum was separated by centrifugation at 2000 × g for 10 min and immediately stored at −20°C. The families of the control and schizophrenic subjects provided written informed consent to allow the use of the brain tissues and serum of these patients as materials for investigation. All of the experiments were performed under the authorization of the Matsuzawa Hospital Ethics Committee and Niigata University Medical Ethics Committee.
Neuroleptic treatment of animals
Male Wistar rats (7 weeks old, initial weight 200-220 g) were housed under a 12-h light-dark cycle with free access to food and water. The rats were treated orally with either haloperidol (target dose, 1-2 mg kg
mixed with food pellets or food pellets alone for 6 months. Different groups of rats were also given either haloperidol (0.5 mg kg
) or vehicle intraperitoneally for 2 weeks. 36 The brains of these animals were harvested rapidly following decapitation and each brain region was dissected on ice. Blood samples were also collected from the rats' tails. The serum was separated using the same method as for human samples. All the animal experiments were performed in accordance with the Animal Use and Care Committee Guidelines of Niigata University.
Enzyme immunoassay
For determination of growth factor concentrations, brain tissues were homogenized in 20-50 volumes of homogenization buffer (phosphate-buffered saline, PBS) containing protease inhibitors (aprotinin (200 kallikrein U ml −1 ), 0.1 mM phenylmethylsulfonyl fluoride, 0.1 mM benzethonium chloride, 1 mM benzamidine (Sigma Chemical Co, St Louis, MO, USA), and 1 mM ethylenediaminetetraacetic acid). Brain homogenates were centrifuged at 14000 × g for 30 min at 4°C and the supernatants were stored at −80°C until use. The protein concentrations in the samples were determined using a Micro BCA kit (Pierce, Rockland, IL, USA) with bovine serum albumin as a standard.
Growth factor levels were measured by sandwich enzyme immunoassay (EIA), as described previously. 37 In brief, tissue extracts (100 l of 1.4-1.5 mg ml −1 protein; duplicate runs), serum (100 l, typically diluted to one tenth; duplicate runs), or growth factor standards (0.1-300 pg; triplicate runs) were loaded into wells of EIA titer plates that had been coated (30-80 ng well ) with anti-human EGF (anti-hEGF; Ab3, Oncogene, Cambridge, MA, USA), anti-hHB-EGF (R&D Systems, Minneapolis, MN, USA) or anti-hTGF␣ (Ab4, Oncogene) antibodies (as a primary antibody). Biotinylated anti-hHB-EGF (R&D Systems) and anti-hTGF␣ (R&D Systems) antibodies (secondary antibody, 3-14 ng ml ) were added to the wells and allowed to bind to HB-EGF and TGF␣, respectively. The biotinylated secondary antibodies were detected using streptavidin-␤-galactosidase (1: 10 000, Sigma, St Louis, MO, USA). Alternatively, the secondary antibody for EGF (R&D Systems) was detected using anti-mouse IgG-␤-galactosidase (1: 1000, Sigma). The ␤-galactosidase activity retained in each well was measured by incubation with 200 mM 4-methylumbelliferyl-␤-D-galactosidase (Sigma). The amount of the resulting fluorescent product was monitored using a Fluorolite-1000 fluorometer (Dynatech Laboratories, Chantilly, VA, USA) with excitation at 364 nm and emission at 448 nm. All the EIAs had a minimum dynamic range of at least 100-fold covering concentrations of 1-100 pg well −1 , and there was no significant crossreactivity among the EGF family members. 37 The average of two measurements per sample was normalized based on the protein concentration. The EIA assays were all performed blind. Western-blot analysis Protein levels of ErbB families and neuron-specific enolase (NSE, for standardization) were determined by Western-blot analysis using methods similar to those described previously. 38 Protein samples for Western
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blotting were prepared from the same tissue extracts as for the two site EIAs by denaturing them with 2% sodium dodecyl sulfate (SDS), separated by SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to a nitrocellulose membrane (Schleicher and Schull, Dassel, Germany) by electrophoresis. The membrane was stained with Ponceau Red to confirm equal protein transfer and the quality of the sample proteins. The membrane was then probed with anti-EGFR antibody (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Neu antibody (1:1000, Santa Cruz Biotechnology), anti-ErbB-3 antibody (1:1000, Santa Cruz Biotechnology), anti-ErbB-4 antibody (1:1000, Santa Cruz Biotechnology), or anti-NSE antibody (1:2000, Chemicon, Temecula, CA, USA). After extensive washing, immunoreactivity on the membrane was detected with anti-rabbit/mouse immunoglobulin conjugated to horseradish peroxidase, followed by a chemiluminescence reaction (ECL kit, Amersham, UK). Densitometric quantitation of band intensities was performed. The level of the internal control NSE, expressed as a percentage of the standard samples, was also used to normalize each value.
Statistical analysis
A Mann-Whitney test (for non-parametric data) or Student's t-test (for parametric data) was used to compare protein levels (receptors), age, postmortem intervals (PMI), and storage time between schizophrenic and control groups. The relation between protein level and age, PMI, storage time, and gender was assessed using Spearman's coefficient. Brain growth factor levels were analyzed using three way-and two-way analysis of variance (ANOVA), followed by Scheffe's post hoc test, for comparisons between the level of growth factor in different regions per diagnosis. A probability level of less than 0.05 was considered to be statistically significant.
Results
We measured the protein levels of three members of the EGF family (EGF, HB-EGF, and TGF␣) in four brain regions (prefrontal cortex, putamen, hippocampus, and cingulate cortex) where pathology in schizophrenia has often been reported. 39 Postmortem samples of each brain region were obtained randomly from 14-17 chronic schizophrenics and from 12-16 controls with no history of neuropsychiatric disorders; neither group had any neurodegenerative features (Table 1) . There was a significant sampling difference in PMI and storage time between the two groups for the prefrontal cortex (storage time) and hippocampus (PMI and storage time), but all other indices were similar (Table 2) . There was no significant correlation, however, between growth factor levels and those indices within the prefrontal cortex (−0.063 Ͻ r Ͻ 0.107, P Ͼ 0.60 for storage time) or the hippocampus (−0.061 Ͻ r Ͻ 0.205, P Ͼ 0.263 for storage time, 0.001 Ͻ r Ͻ 0.236, P Ͼ 0.209 for PMI). Therefore, the 3-way ANOVA was applied to diagnosis group, growth factor, and brain The number of serum samples tested total 55 (M32, F23), but whose raw measurements varied significantly in a duplicated EIA were not adopted as data.
region. There was a significant difference between the diagnosis groups (F(1,347) = 7.633, P = 0.0061). For each growth factor, a two-way ANOVA was applied for subsequent statistical analyses. Only EGF levels were significantly affected; F(1,115) = 4.39, P = 0.038. Posthoc analysis revealed that EGF protein levels were significantly decreased in the frontal cortex (P Ͻ 0.05) and putamen (P Ͻ 0.001), but not in the hippocampus or cingulate cortex of the schizophrenics compared with controls ( Figure 1a ). When we focused the study on cases where prefrontal cortex and putamen samples were both available, two-way ANOVA with repeated measure indicated the same results (F(1,37) = 16.1, P = 0.0003). There was no difference between groups in the levels of the other members of the EGF family (HB-EGF and TGF␣) in any of the regions examined. Even
Molecular Psychiatry Figure 1 Protein levels of EGF family members in the brains of schizophrenic patients and haloperidol-treated rats. (a) Scatterplots displaying variability and differences in the levels of EGF, HB-EGF, and TGF␣ in the schizophrenic and control subjects. Significant difference from controls is indicated as follows: *P Ͻ 0.05, ***P Ͻ 0.001, three-way and two-way ANOVA followed by post-hoc analysis. though EGF abnormality might be associated with schizophrenic patients, neuroleptic treatment could potentially cause the abnormality and this was also evaluated in the present study. To assess the influence of neuroleptics, haloperidol, the antipsychotic preferentially administered to the patients, was given to adult rats for 2 weeks (Figure 1b) . EGF levels were measured in the same brain regions of these rats. Haloperidol had no significant effect on any of the growth factors in any of the brain regions examined.
There is considerable feedback regulation between ligand stimulation and EGFR expression. 40 Enhanced EGF signals down-regulate the production of the EGFR (or ErbB1) subunit in the brain, thereby desensitizing EGF signaling. EGF binds to a single EGFR subunit and triggers its homomeric or heteromeric dimerization with another EGF receptor subunit, such as ErbB2 (Neu), ErbB3, or ErbB4. [41] [42] [43] To evaluate the influence of schizophrenia on all of the ErbB family proteins, we performed Western-blot analysis on all of the samples, but only display the data for the prefrontal cortex, where there was a significant difference in ligand EGF levels ( Figure 2 ). EGFR protein was detected as a 170-kDa band, which is consistent with the apparent molecular size of non-truncated EGFR. 44, 45 There was no significant correlation between ErbB family receptor levels and their ligands or brain regions with regard to the diagnosis. Therefore, an analysis of these data was performed using univariate analysis (Mann-Whitney U-test). EGFR immunoreactivity in the prefrontal cortex was significantly higher in the schizophrenics than in the controls (94.0% increase, U = 42, P Ͻ 0.05).
There was a similar trend of increased ErbB3 levels in the prefrontal cortex, but this was not statistically significant (P = 0.072). There was no interaction between EGF levels and EGFR immunoreactivity, however, in the prefrontal cortex (Spearman's correlation r = −0.256, P = 0.199). The influence of haloperidol on EGFR subunits was tested in the same rat brain samples (Figure 2c ). Haloperidol failed to influence the expression of EGFR protein as well as that of the other subunits in rats, suggesting that the up-regulation of EGFR observed in schizophrenic patients was not due to patients' medication. The up-regulation of EGFR that is associated with the disease itself confirms that the EGF signaling pathway is impaired in schizophrenia. EGF family proteins are also highly expressed in blood cells. 46 To evaluate the peripheral and developmental influences of schizophrenia on these ligands, serum samples were collected from a larger number of chronic schizophrenic patients as well as from nontreated young patients (Table 2 ). In chronic schizo- Figure 2 Impaired expression of EGF receptor subunits in schizophrenics. Receptor subunits in the EGF receptor complex were detected by Western-blot analysis in the brain homogenates from the prefrontal cortex, striatum, hippocampus, and cingulate cortex in schizophrenics and controls. Only results from the prefrontal cortex that exhibited significant differences in this analysis are shown. The protein was separated by SDS/PAGE on an 8% gel, transferred to a nitrocellulose membrane, or incubated with anti-EGF receptor, anti-Neu, anti-ErbB3, and anti-ErbB4 antibodies, as well as with anti-NSE antibody as an internal control. Immunoreactivity was measured by densitometric analysis and standardized against that of the internal control, NSE, to control for variation of protein loading/blotting and degradation among postmortem samples. (a) Scatterplots displaying the variability and differences in the levels of ErbB family proteins in the schizophrenic and control subjects. Normalized densitometoric measurement data are shown (n = 12 for control, n = 14 for schizophrenic group). Solid triangles, schizo- −1 daily), was given chronically to adult male rats (n = 5 per group). There was no significant difference (by Mann-Whitney Utest) between haloperidol-treated and control rats (n = 5 per group) in any of the examined regions including striatum, hippocampus, and cingulate cortex (data not shown). ). FC, prefrontal cortex; STR, putamen; HIP, hippocampus; CC, cingulate cortex; CON, control; SCZ, schizophrenia. Significantly different from controls (*P Ͻ 0.05, ***P Ͻ 0.001, Two-way ANOVA post-hoc Scheffe's method for brain analysis, Mann-Whitney U-test for serum analysis).
Figure 3
Reduction in serum EGF levels in schizophrenic patients. Scatterplots display the variability and differences in the serum levels of EGF, HB-EGF, and TGF␣ in the schizophrenic and control subjects. HB-EGF (a), TGF␣ (b) and EGF (c) levels were measured in serum of healthy volunteers (open circles) and age-matched medicated patients (solid triangles). In this experiment, only EGF levels were significantly different between control and patient groups. Samples whose raw measurements varied (see Table 3 ) significantly in a duplicated EIA were excluded for data analysis. In (d) serum EGF levels were measured similarly in young healthy volunteers (n = 14; open circles) and age-matched drug-naive patients (n = 6; solid triangles). In adult rats (e), the effect of chronic haloperidol treatment on serum EGF levels was assessed. Serum EGF levels were measured in haloperidol-treated rats (for 6 months, target dose; 1-2 mg kg −1 daily) (open circles; n = 9) and age-matched healthy rats (solid diamonds; n = 9). The chronic treatment with haloperidol failed to affect EGF levels in rat serum. EGF levels were 542 ± 121 pg ml −1 in control rats and 517 ± 50.3 pg ml −1 (mean ± SD) in haloperidol-treated rats. See Tables 2 and 3 for all the information on these blood samples.
phrenic patients, only EGF levels in the serum were markedly decreased (65% reduction, n = 45 each, U = 1590.5, P Ͻ 0.001) (Table 3, Figure 3 ). There was no significant difference in HB-EGF or TGF␣ levels between the two groups. The sera from drug-naive (n = 4) and drug-washout (over 14 months, n = 2) patients were also tested independently. As in chronic patients, the mean EGF level in the drug-naive schizoMolecular Psychiatry phrenic patients was lower than in age-and gendermatched controls (Table 3 , Figure 3c, d ). Again, we tested the long-term effect of haloperidol on serum EGF. Rats were given haloperidol orally for 6 months before their blood was collected (n = 9). Consistent with its effects in humans, serum EGF levels were not changed, despite prolonged administration of the drug (Figure 3e ).
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Discussion
Using two-site EIAs, we demonstrated that EGF levels were significantly decreased in the brain (47.1% decrease in the putamen and 24.5% decrease in the prefrontal cortex) of schizophrenics compared to controls. There was a similar trend in the peripheral samples: serum EGF levels were also significantly decreased (65% reduction) in schizophrenic patients. Even in the sera of drug-free patients, EGF levels were significantly lower than in age-matched controls. Previous pathologic examinations indicate that changes in several molecular markers often represent the influences of chronic medication rather than the pathology of schizophrenia. 47, 48 In the present study, however, the potential involvement of medication is not likely because chronic treatment with a typical neuroleptic, haloperidol, failed to alter EGF protein concentrations in either rat brain or serum. Together these observations strongly suggest that the expression of EGF is impaired in both the central and peripheral organs of schizophrenic patients, irrespective of their medical treatment.
The technical limitations of using postmortem samples must also be considered. 49 There was a difference in PMI and storage time between the two groups, but several lines of evidence indicate that our finding was unlikely to be the result of prolonged PMI or storage time. Correlation analysis revealed that PMI and storage time did not affect growth factor levels in any brain region in either the schizophrenics or control subjects. Moreover, it is quite unlikely that the longer PMI and storage time observed in schizophrenic samples would have led to a region-specific decrease in levels of EGF, but no decrease in other growth factors. Because of the regional specificity of the EGF alteration, it is also unlikely that the reduction in EGF levels in the prefrontal cortex and striatum reflect EGF changes in the blood remaining in the postmortem samples. Consistent with this, we estimated that the ratio of blood contamination in the brain samples was less than 1% of the volume of the tissue (data not shown). Therefore, the contamination of blood-derived EGF was almost negligible in the present study. Correlation analysis revealed that there was a positive correlation between duration of illness and EGF level in the prefrontal cortex of schizophrenic subjects (r = 0.604, P Ͻ 0.05). The longer duration of illness in the schizophrenic patients tended to elevate EGF levels. Accordingly, the reduction in brain EGF observed in schizophrenic patients cannot be attributed to their long duration of illness. The other growth factors in each region were not correlated with duration of illness in the schizophrenic subjects. There were no effects of chronic treatment with antipsychotic drugs on levels of brain and serum growth factors in animals. Similarly, there was no correlation between the dose of antipsychotics (converted to haloperidol equivalent) and all protein levels we examined in schizophrenia patients.
The expression of high-affinity EGFR was increased in the prefrontal cortex of schizophrenics while the concentration of its ligand, EGF, was decreased in this region. Although it is uncertain whether the up-regulation of EGFR resulted from the decreased release of EGF in patients or reflected an etiologic defect of its regulation, EGFR up-regulation in schizophrenia confirms that EGF signaling is impaired in schizophrenic patients. It remains to be determined why EGF production in those forebrain regions and in the peripheral blood is subject to similar regulation. EGF family proteins are released not only from secretory vesicles but also from membrane-anchored precursor proteins by the proteolytic process called shedding. 50 Among these proteins, HB-EGF is the best characterized factor that is released from the cell surface in response to the stimulation of G-proteincoupled receptors. 51 The decrease in EGF levels might reflect alterations in post-translational processing rather than in gene expression. Our preliminary studies suggest that such post-translational modification is likely to be involved in the EGF abnormality observed in schizophrenia (data not shown). In addition, decreased serum EGF might be associated with an altered risk for other diseases in schizophrenic patients, 52, 53 as this factor exerts a broad range of biologic activities. 1, 2 Developmental brain defects as well as dopaminergic dysfunction are thought to have a role in the etiology of schizophrenia. [54] [55] [56] [57] Previous neurobiological studies have demonstrated that peptides from the EGF family exert neurotrophic effects on developing dopaminergic neurons in vitro and in vivo. 4, [13] [14] [15] [16] In embryonic mesencephalon culture, EGF specifically enhances cell survival of dopamine neurons. 13 Intraventricular infusion of EGF elevates striatal innervation by dopaminergic fibers from the substantia nigra. 15 This is consistent with findings from TGF␣-null-mutant mice, which have decreased numbers of midbrain dopaminergic neurons. 18 These observations suggest that there is a strong relationship between EGF signals and dopaminergic development in the CNS. In the present study, the decrease in EGF levels was evident in the putamen as well as in the prefrontal cortex, both of which are main target areas of dopaminergic projections. Although it is still uncertain whether increased receptor number or decreased ligand concentration has a more dominant role in schizophrenia, the abnormal up-regulation of EGFR expression is more consistent with the dopaminergic hyper-function hypothesis of schizophrenia.
The molecular and cellular targets of impaired EGF signaling in schizophrenic pathology remain to be identified, however. The above scenarios of EGF might be important in brain malformations or in the dopaminergic dysfunction observed in schizophrenic patients. Taken together, the EGF/EGFR abnormality observed in schizophrenic patients might provide a molecular basis for both the structural and phenotypic impairments observed in this disease, although this etiologic argument is assumptive and remains to be examined experimentally. Future studies are required to address the question of how impaired EGF/EGFR signaling leads to neurochemical or functional defects in the brains of schizophrenic patients.
